Catheter Precision recently announced it expanded its U.S. customer base for the Vivo non invasive 3D imaging system.
Vivo is a non-invasive 3D imaging system that allows physicians to identify the location of arrhythmias pre-procedure. It received FDA clearance at the end of 2020 and was strategically launched in the U.S. in 2021. Vivo has also been awarded CE mark approval.
“Conventional invasive mapping can be both time-consuming and unsuccessful for arrhythmia localization. In clinical studies Vivo has shown an up to 30% reduction in mapping time, which we see as a clear advantage for arrhythmia procedures. We chose to conduct a limited launch with VIVO to ensure our clinical teams were effective in gaining clinical acceptance while building customer demand,” CEO David Jenkins said in a news release.
In September, Catheter Precision announced a definitive merger agreement with Ra Medical Systems. Through the deal, Catheter Precision will become a wholly owned subsidiary of Ra Medical Systems in the stock-for-stock reverse merger transaction. The companies anticipate the merger to close before the end of the calendar year.
“Based on our initial success, we believe our strategy is working in the U.S. Even more promising, our current customers continue to order the single use disposable accessory, providing us an additional revenue stream and further validation of Vivo’s clinical acceptance as a valued tool prior to a ventricular ablation. With successful completion of the merger, we look forward to expanding our sales team and ramping our commercial activities in early 2023.”
To date, Catheter Precision said the Vivo device has been used in more than 780 procedures and anticipates 2022 revenue in the range of $230,000 to $270,000.
